Insider Transactions in Q1 2022 at Organogenesis Holdings Inc. (ORGO)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Open market or private sale
|
Direct |
97,436
-68.75%
|
$779,488
$8.39 P/Share
|
|
Mar 10
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Exercise of conversion of derivative security
|
Direct |
68,504
+20.76%
|
$205,512
$3.46 P/Share
|
|
Mar 09
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Open market or private sale
|
Direct |
10,000
-12.02%
|
$80,000
$8.52 P/Share
|
|
Feb 16
2022
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,085
-0.99%
|
$28,595
$7.78 P/Share
|
|
Feb 16
2022
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
953
-1.74%
|
$6,671
$7.78 P/Share
|
|
Feb 16
2022
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-1.01%
|
$5,355
$7.78 P/Share
|
|
Feb 16
2022
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
937
-0.5%
|
$6,559
$7.78 P/Share
|
|
Feb 16
2022
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-0.89%
|
$5,593
$7.78 P/Share
|
|
Feb 16
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
718
-0.86%
|
$5,026
$7.78 P/Share
|
|
Feb 15
2022
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
280,199
+40.47%
|
-
|
|
Feb 15
2022
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,876
-3.31%
|
$15,008
$8.03 P/Share
|
|
Feb 15
2022
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,348
+41.57%
|
-
|
|
Feb 15
2022
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,843
+35.63%
|
-
|
|
Feb 15
2022
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,926
+22.1%
|
-
|
|
Feb 15
2022
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,143
+33.47%
|
-
|
|
Feb 15
2022
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
14,383
+14.63%
|
-
|
|
Feb 15
2022
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+23.24%
|
-
|
|
Feb 15
2022
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+44.27%
|
-
|
|
Feb 15
2022
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+39.19%
|
-
|
|
Feb 15
2022
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,547
+50.0%
|
-
|